Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9610MR)

This product GTTS-WQ9610MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9610MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11039MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ10348MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ7077MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ136MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ8474MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1200MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ756MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ2738MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW